PhilArt next
is an innovative viscological, apirogenic, sterile polynucleotide gel designed for intradermal administration. It contains a unique combination of polynucleotide (10 mg/ml) and hyaluronic acid (10 mg/ml) which act synergistically, offering advanced hydration, nutrition and skin regeneration.
Moisture and nutrition
PhilArt Next deeply moisturizes the skin, thanks to its hyaluronic acid content, which intensively hydrates tissues, and polynucleotides that nourish fibroblasts.
Improving flexibility
Regular use leads to a noticeable improvement in skin elasticity and tension, thanks to the synergistic effect of polynucleotides and hyaluronic acid.
Universal Application
Ideal for use on mature skin with signs of aging, helping to correct medium and deep wrinkles and remodel scars and stretch marks.
Application:
- improving skin elasticity and tension
- moisturizing and nourishing the skin
- reconstruction of stretch marks and after-treatment scars
Area of application:
- face:
- including tear valley deformations
- neck
- cleavage
- hands
Composition:
- Polynucleotides (10 mg/ml)- natural substances that moisturize and nourish the skin, supporting regeneration
- Hyaluronic acid (10 mg/ml)- maintains hydration and elasticity of the skin, slowing down the aging process
Ingredients (INCI):
Polynucleotides, Sodium Hyaluronate, Mannitol, Aqua, Sodium Chloride, Sodium Dihydrogen Phosphate Digate, Disodium Phosphate Dodecahydrate
Method of use:
- Depending on the assessment, different injection techniques such as linear, micro piercing, cross-linked, fan or mixed techniques may be used
- the possibility of using modern non-invasive techniques such as ionophoresis, electroporation, hydroelectrophoresis
- individualized treatment programs are recommended depending on skin condition and customer needs
Packaging:
- 1 x 2 ml pre-filled syringe
- 2 x needle 2 x 30G 1/2, 13 mm
The product can be used only by professionals.
By making a purchase, you declare yourself a doctor or cosmetologist trained in aesthetic medicine.
